New Delhi:Slashing of prices of 27 scheduled formulations used in common medicines by the NPPA, has lessened costs of insulin, oral rehydration solution (ORS), antibiotic, folic acid health supplements and 23 other formulations.
The lessening of prices by 48% , of 27 formulations by the National Pharmaceutical Pricing Authority is going to bring relief to patients suffering from both critical and common diseases.
Moxikind, Electral, Filvite, Zifi, Brutaflam, Novamox and Insugen are some of the household brands, out of the 150 drugs that are going to come cheaper, due to the NPPA directive.
The critical ailment formulations included in this price slash drive include- cardiac disorders, rheumatoid arthritis, cancer and Parkinson’s Disease.
Eyedrops using Travoprost, a hypertension patient’s drug, has come down 48% in terms of price; while pegylated liposomal doxorubicin injection used for certain kinds of cancer (including ovarian), antibiotics and insulin will witness a 12%, 13% and 3% deduction in price, respectively.
“We are systematically working with an aim to bring down the prices of drugs. The idea is to make treatment of critical diseases,as well as, regular diseases, burden-free,” Bhupendra Singh, Chairman of NPPA, told HT in April.
According to data reflecting the National Health Profile 2015, compiled by the Central Bureau of Health Intelligence, rural India’s, out of-pocket expenditure on medicine is 80% of its total income; while in urban areas, it amounts to 75%, as reported by Hindustan Times.
The revised price list notification was released on May 21. In a recent order, the regulator mandated chemists and druggists to pass on all price revisions to consumers.
280 new drugs have so far been capped by the NPPA, as part of the revision exercise.This being the third price revision in the last one month. On May 9, the regulator fixed prices of 54 drugs.
The revised National List of Essential Medicines,2015 incorporates these 27 formulations. The Ministry of Health and Family Welfare, in December, raised the number of medicines under price control from 684 to 875.